Top Stories
L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM
Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM
Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

Dr. Reddy's Q2FY24 Financial Performance Review
In this financial performance review, we delve into the results of Dr. Reddy's for the second quarter of fiscal year 2024 and analyze key metrics, including revenue, expenses, net profit, and margin.
Particulars | Q2FY23 | (Y-o-Y) % change | Q1FY24 | (Q-o-Q) % change | Q2FY24 |
Total Income (₹crs.) | 6,305.70 | 9.11 | 6,738.40 | 2.1 | 6,880.20 |
Operating Profit (₹crs.) | 1,612.70 | 10.79 | 1,763.60 | 1.31 | 1,786.70 |
Net Profit (₹crs.) | 1,112.8 | 33 | 1402.5 | 5.53 | 1480 |
Margin (%) | 17.65 | 3.86 | 20.81 | 0.70 | 21.51 |
REVENUE:
Dr. Reddy's reported a total income of ₹6,880.20 crores for Q2FY24, reflecting a stable 2.1% increase compared to the preceding quarter, Q1FY24. On a year-on-year basis, the company showcased a healthy 9.11% growth in total income compared to the same quarter in the previous fiscal year, Q2FY23.
OPERATING PROFIT:
The operating profit for Dr. Reddy's in Q2FY24 was ₹1,786.70 crores, marking a 1.31% increase compared to the preceding quarter, Q1FY24. Year-on-year, the company demonstrated a solid 10.79% growth in operating profit, showcasing efficiency in its operations.
NET PROFIT:
The net profit of Dr. Reddy's for Q2FY24 stood at ₹1,480 crores, displaying a 5.53% increase compared to the preceding quarter, Q1FY24. On a year-on-year basis, the company exhibited significant growth with a remarkable 33% increase in net profit, indicating strong financial performance.
MARGINS:
Dr. Reddy's margin in Q2FY24 was 21.51%, a 0.70% increase compared to the preceding quarter, Q1FY24. Year-on-year, the company significantly improved its margin, with a growth of 3.86%, underlining its focus on profitability and operational excellence.
In conclusion, Dr. Reddy's financial performance in Q2FY24 reflects robust growth and an increase in profitability. The company's ability to expand revenue, improve margins, and efficiently manage operating profit is commendable.
Stay tuned for more detailed updates on Dr. Reddy's financial performance in the coming quarters.
Related News

BLS's Q2FY24 Financial Performance Review
2 mins read. November 6, 2023 at 08:56 AM

Interglobe Aviation's Q2FY24 Financial Performance Review
2 mins read. November 3, 2023 at 11:31 AM

Titan's Q2FY24 Financial Performance Review
2 mins read. November 3, 2023 at 10:59 AM

Zomato's Q2FY24 Financial Performance Review
3 mins read. November 3, 2023 at 09:50 AM
Download app
Access BlinkX
everywhere
across device
